000050143 000__ 02614nam\a2200409\i\4500
000050143 001__ 50143
000050143 003__ SzGeWIPO
000050143 005__ 20241024004424.0
000050143 006__ m    eo  d        
000050143 007__ cr bn |||m|||a
000050143 008__ 241007s2024\\\\enk\\\\\o\\\\\000\0\eng\d
000050143 0247_ $$a10.1093/grurint/ikae092$$2doi
000050143 035__ $$a(OCoLC)1463455805
000050143 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000050143 041__ $$aeng
000050143 24502 $$aA Regulatory Governance Perspective on IP and Access to Medicines :$$bA Fresh Look Into the TRIPS Agreement.
000050143 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2024.
000050143 300__ $$a1 online resource (pages  817-823)
000050143 336__ $$atext$$2rdacontent
000050143 337__ $$acomputer$$2rdamedia
000050143 338__ $$aonline resource$$bcr$$2rdacarrier
000050143 4901_ $$aGRUR International,$$x2632-8550 ;$$v73, 9, 2024
000050143 520__ $$aAs concerns the relationship between the Global South and the developed countries, the TRIPS Agreement provides a robust protection of IP. This might result in a weaker protection of fundamental rights, such as health, in those countries that do not possess the necessary know-how and industrial capacity to manufacture essential medicines. The recent Decision adopted at the 12th WTO Ministerial Conference provides the opportunity to focus again on the topic and deal with the issue of the clash between IP and the national interests of the least developed countries. Instead of addressing the problem by looking at the well-known flexibilities/inflexibilities of the Agreement, this paper proposes a different methodological approach that builds on the flourishing literature on regulatory governance. To this end, a multi-dimensional regulatory approach is suggested that simultaneously exploits a matrix of normative, market-based and cooperative instruments. While we wait for a more structural normative reform, a similar perspective not only proves to be useful from a theoretical perspective, but could also contribute to shedding a new light on the TRIPS Agreement.
000050143 542__ $$fhttps://academic.oup.com/grurint/article/72/3/231/6998505
000050143 588__ $$aCrossref
000050143 590__ $$aPublished online: 19-Jul-24
000050143 650_4 $$aTrade-Related Aspects of Intellectual Property (TRIPS)
000050143 650_0 $$aPharmaceutical policy.
000050143 650_0 $$aIntellectual property.
000050143 650_0 $$aCopyright.
000050143 7001_ $$aGhidini, Gustavo,$$eauthor.
000050143 7001_ $$aPiselli, Riccardo,$$eauthor.
000050143 7731_ $$tGRUR International$$wGRUR
000050143 830_0 $$aGRUR International ;$$v73, 9, 2024,$$x2632-8550.
000050143 85641 $$uhttps://doi.org/10.1093/grurint/ikae092$$yonline version
000050143 904__ $$aJournal article
000050143 980__ $$aGRUR